Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
0.2500
+0.0549 (28.14%)
At close: Apr 1, 2025, 4:00 PM
0.2612
+0.0112 (4.48%)
After-hours: Apr 1, 2025, 7:54 PM EDT

Protagenic Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
1.221.211.9731.851.28
Upgrade
Research & Development
4.053.321.591.140.70.81
Upgrade
Operating Expenses
5.274.533.564.142.552.09
Upgrade
Operating Income
-5.27-4.53-3.56-4.14-2.55-2.09
Upgrade
Interest Expense
-0.01-0.11-0.14-0.5-0.25-0.02
Upgrade
Interest & Investment Income
0.090.260.190.0300
Upgrade
Other Non Operating Income (Expenses)
---0.080.250.34
Upgrade
EBT Excluding Unusual Items
-5.19-4.37-3.51-4.52-2.55-1.76
Upgrade
Gain (Loss) on Sale of Investments
-0.43-0.63-0.05-0-0
Upgrade
Pretax Income
-5.65-5-3.56-4.52-2.55-1.75
Upgrade
Net Income
-5.65-5-3.56-4.52-2.55-1.75
Upgrade
Net Income to Common
-5.65-5-3.56-4.52-2.55-1.75
Upgrade
Shares Outstanding (Basic)
444433
Upgrade
Shares Outstanding (Diluted)
444433
Upgrade
Shares Change (YoY)
2.87%0.62%17.17%42.57%0.76%-
Upgrade
EPS (Basic)
-1.27-1.15-0.82-1.23-0.99-0.68
Upgrade
EPS (Diluted)
-1.27-1.15-0.82-1.23-0.99-0.68
Upgrade
Free Cash Flow
-4.64-3.85-2-2.8-1.35-0.49
Upgrade
Free Cash Flow Per Share
-1.04-0.89-0.46-0.76-0.52-0.19
Upgrade
EBITDA
-5.21-4.5-3.56-4.14-2.55-2.09
Upgrade
D&A For EBITDA
0.060.030000
Upgrade
EBIT
-5.27-4.53-3.56-4.14-2.55-2.09
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q